Grant H Louie1, Michael M Ward. 1. aDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore bIntramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the development of spinal new bone formation. Recent observational studies are compared with the results from clinical trials for the effects of tumor necrosis factor-alpha inhibitors (TNFi) and NSAIDs on radiographic measures of spinal damage. RECENT FINDINGS: Data from clinical trials indicate that treatment up to 2 years with TNFi was not associated with a difference in rates of progression of spinal damage, compared with historical controls. These studies were based on open-label extensions, and analyzed as cohort studies. Recent observational studies have suggested that TNFi may reduce radiographic progression. The different conclusions may be related to the longer treatment and observation period of these observational studies, which may have permitted detection of changes in this slowly evolving process. There is emerging evidence from a clinical trial and retrospective studies that continuous NSAID use may slow radiographic progression. SUMMARY: Lack of evidence that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may be because of the design of these studies, and possibly not a true null treatment effect.
PURPOSE OF REVIEW: One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the development of spinal new bone formation. Recent observational studies are compared with the results from clinical trials for the effects of tumor necrosis factor-alpha inhibitors (TNFi) and NSAIDs on radiographic measures of spinal damage. RECENT FINDINGS: Data from clinical trials indicate that treatment up to 2 years with TNFi was not associated with a difference in rates of progression of spinal damage, compared with historical controls. These studies were based on open-label extensions, and analyzed as cohort studies. Recent observational studies have suggested that TNFi may reduce radiographic progression. The different conclusions may be related to the longer treatment and observation period of these observational studies, which may have permitted detection of changes in this slowly evolving process. There is emerging evidence from a clinical trial and retrospective studies that continuous NSAID use may slow radiographic progression. SUMMARY: Lack of evidence that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may be because of the design of these studies, and possibly not a true null treatment effect.
Authors: Jennifer H Jang; Michael M Ward; Adam N Rucker; John D Reveille; John C Davis; Michael H Weisman; Thomas J Learch Journal: Radiology Date: 2010-10-22 Impact factor: 11.105
Authors: Denis Poddubnyy; Martin Rudwaleit; Hildrun Haibel; Joachim Listing; Elisabeth Märker-Hermann; Henning Zeidler; Jürgen Braun; Joachim Sieper Journal: Ann Rheum Dis Date: 2012-03-29 Impact factor: 19.103
Authors: Pedro Machado; Robert Landewé; Jürgen Braun; Kay-Geert A Hermann; Daniel Baker; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2010-05-24 Impact factor: 19.103
Authors: Walter P Maksymowych; Praveena Chiowchanwisawakit; Tracey Clare; Susanne J Pedersen; Mikkel Østergaard; Robert G W Lambert Journal: Arthritis Rheum Date: 2009-01
Authors: Jürgen Braun; Xenofon Baraliakos; Kay-Geert A Hermann; Désirée van der Heijde; Robert D Inman; Atul A Deodhar; Anna Baratelle; Stephen Xu; Weichun Xu; Benjamin Hsu Journal: Ann Rheum Dis Date: 2011-11-29 Impact factor: 19.103
Authors: Désirée van der Heijde; David Salonen; Barbara N Weissman; Robert Landewé; Walter P Maksymowych; Hartmut Kupper; Shaila Ballal; Eric Gibson; Robert Wong Journal: Arthritis Res Ther Date: 2009-08-24 Impact factor: 5.156
Authors: Xenofon Baraliakos; Joachim Listing; Martin Rudwaleit; Joachim Sieper; Juergen Braun Journal: Arthritis Res Ther Date: 2008-09-01 Impact factor: 5.156